Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion studyUdai Banerji, Philippe Aftimos, Carla M.L. van Herpen et al.|The Lancet Oncology|2019Cited by 564
Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid TumorsThierry André, Susana Banerjee, Dominique Berton et al.|JAMA Network Open|2023Cited by 120
Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumorsAlbiruni RA Razak, Kyriakos P. Papadopoulos, Jeanne Tie et al.|Journal for ImmunoTherapy of Cancer|2020Cited by 117
First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody–Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid TumorsMichael L. Maitland, Emiliano Calvo, Jasgit C. Sachdev et al.|Clinical Cancer Research|2021Cited by 81
Revolutionizing anti-HER2 therapies for extrahepatic cholangiocarcinoma and gallbladder cancer: Current advancements and future perspectivesB. Ten Haaft, Ángela Lamarca, Manuel Pedregal et al.|European Journal of Cancer|2024Cited by 50